Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie Reports Third-Quarter 2024 Financial Results
07:38am, Wednesday, 30'th Oct 2024
Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of $0.04
3 Dividend Growth Stocks to Buy and Never Sell
07:00am, Wednesday, 30'th Oct 2024
These 3 dividend growth stocks have crushed the market and show no signs of slowing down.
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
12:15pm, Tuesday, 29'th Oct 2024
AbbVie Inc ABBV will be reporting its third-quarter earnings on Wednesday. Wall Street expects $2.92 in EPS and $14.28 billion in revenues as the company reports before market hours.
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?
01:10pm, Monday, 28'th Oct 2024
Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.
AbbVie to buy Alzheimer's therapy developer Aliada Therapeutics for $1.4 bln
08:21am, Monday, 28'th Oct 2024
U.S. drugmaker AbbVie said on Monday it would acquire Aliada Therapeutics for $1.4 billion in cash, gaining access to the therapy developer's Alzheimer's disease drug candidate.
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
08:00am, Monday, 28'th Oct 2024
Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize Aliada'
3 Dividend Growth Stocks You Can Buy and Hold Forever
07:30am, Saturday, 26'th Oct 2024
These healthcare stocks have fantastic dividend track records.
Final Trades: Tesla, Sweetgreen, AbbVie and Digital Realty
01:26pm, Friday, 25'th Oct 2024
CNBC's Investment Committee join 'Halftime Report' to give you their top stocks to watch.
Curious about AbbVie (ABBV) Q3 Performance? Explore Wall Street Estimates for Key Metrics
10:20am, Friday, 25'th Oct 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for AbbVie (ABBV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua
Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?
10:20am, Friday, 25'th Oct 2024
Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.
3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees
08:30am, Friday, 25'th Oct 2024
These stocks yield between 2.8% and 3.3% in dividends.
AbbVie (ABBV) Outperforms Broader Market: What You Need to Know
06:50pm, Thursday, 24'th Oct 2024
In the closing of the recent trading day, AbbVie (ABBV) stood at $189.65, denoting a +0.94% change from the preceding trading day.
AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
11:30am, Thursday, 24'th Oct 2024
Companies will discover and develop novel targets for the potential treatment of neuropsychiatric conditions New discovery program builds upon nearly two decades of partnership between AbbVie and Ge
AbbVie: Expect A Beat-And-Raise Q3 2024
11:38am, Wednesday, 23'rd Oct 2024
AbbVie will report Q3 2024 results next week and I expect to see a beat-and-raise quarter. The outperformance should be driven by top growth products Skyrizi and Rinvoq, the strong performance of neur
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
11:08am, Wednesday, 23'rd Oct 2024
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
